

# Primary prevention of rheumatoid arthritis.

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Recruiting
<b>Health condition type</b>	-
<b>Study type</b>	Interventional

## Summary

### ID

NL-OMON26301

### Source

NTR

### Brief title

N/A

### Health condition

rheumatoid arthritis

## Sponsors and support

**Primary sponsor:** Prof.dr. B.A.C. Dijkmans  
VUMC/Jan van Breemen Instituut

**Source(s) of monetary or material Support:** ZonMW

## Intervention

## Outcome measures

### Primary outcome

50% reduction of the concentration of the increased antibodies after 6 months compared to no treatment.

### Secondary outcome

Frequency of rheumatoid arthritis after 5 years compared to no treatment.

## Study description

### Background summary

Rheumatoid arthritis (RA) has a preclinical phase. Before the disease manifests itself autoantibodies such as rheumatoid factor (RF) and antibodies against citrullinated proteins (anti-CCP) can be found. In one half of blood donors who developed RA later we found an elevated concentration in serum of RF and/or anti-CCP at an average of five years before the start of the symptoms, whereas control donors hardly had positive results.

The predictive value for the development of RA within five years of a positive test for RF and/or anti-CCP varies from 2% (no risk factors) to 44% (multi-case families). This risk increases further if the genetic risk factor HLA-DR4 is also present. The target group for this study consists of persons with or without joint complaints (possibly with family members with RA), but without

arthritis, and also with both increased values of RF and/or anti-CCP and a positive test for HLA-DR4. These persons have an increased risk of developing RA and therefore can be considered candidates for a preventive intervention.

Such a preventive intervention should be short and safe. Therefore the choice was made for 1-2 injections with a prednisone-like substance, with proven efficacy in patients who already have RA. The goal of this preventive intervention is to achieve a decrease into the normal range or at least a 50% decrease of the concentration of these antibodies after 6 months. It is expected that a decrease of the antibody concentration is a good predictor for the cancellation or the postponement of the development of manifest RA.

In this doubleblind randomised study one hundred persons will be included. These will mainly be family members of RA patients and patients with joint complaints who have been referred by their family physician. After the intervention the participants will be followed for at least five years.

### Study objective

1-2 intramuscular injections with 100 mg dexamethason in persons without arthritis but with elevated serum levels of rheumatoid factor and or anti-CCP will lead to a reduction in antibody concentrations after 6 months and possibly to a lower frequency of rheumatoid arthritis after 5 years, in comparison to no treatment.

### Intervention

1-2 intramuscular injections with 100 mg dexamethason with 6 weeks interval (2nd injection with verum depends on response to first injection) or twice placebo.

## Contacts

### Public

Jan van Breemen Institute,  
Dr. Jan van Breemenstraat 2  
D. Schaardenburg, van  
Dr. Jan van Breemenstraat 2  
Amsterdam 1056 AB  
The Netherlands  
+31 (0)20 5896589

### Scientific

Jan van Breemen Institute,  
Dr. Jan van Breemenstraat 2  
D. Schaardenburg, van  
Dr. Jan van Breemenstraat 2  
Amsterdam 1056 AB  
The Netherlands  
+31 (0)20 5896589

## Eligibility criteria

### Inclusion criteria

1. Age 18-70 years for RF+, 18+ for aCCP+;
2. Twice increased IgM-RF and/or anti-CCP with 4+ weeks interval;
3. HLA-DR SE positive.

### Exclusion criteria

Situations with possible false positive RF:

1. Auto-immune diseases;
2. Active infection with hepatitis C or Epstein Barr virus;
3. Recent chemotherapy;
4. Comorbidity with decreased life expectancy;

5. Corticosteroid use for another disease;
6. Contra-indications for corticosteroids: diabetes mellitus, osteoporosis;
7. Pregnancy or lactation.

## Study design

### Design

Study type:	Interventional
Intervention model:	Parallel
Masking:	Double blinded (masking used)
Control:	Placebo

### Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	01-10-2005
Enrollment:	80
Type:	Anticipated

## Ethics review

Positive opinion	
Date:	23-08-2005
Application type:	First submission

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL102
NTR-old	NTR133
Other	: N/A
ISRCTN	ISRCTN73232918

## Study results

### Summary results

<br>Arthritis Rheum 2004; 50: 380-6

<br>Arthritis Rheum 2004; 50: 2423-7